156 related articles for article (PubMed ID: 34124145)
1. The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer.
Liu Y; Wu H; Luo T; Luo Q; Meng Z; Shi Y; Li F; Liu M; Peng X; Liu J; Xu C; Tang W
Front Mol Biosci; 2021; 8():646542. PubMed ID: 34124145
[TBL] [Abstract][Full Text] [Related]
2. Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription.
Li SN; Yang S; Wang HQ; Hui TL; Cheng M; Zhang X; Li BK; Wang GY
World J Gastrointest Oncol; 2024 Apr; 16(4):1564-1577. PubMed ID: 38660648
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Hu W; Lei L; Xie X; Huang L; Cui Q; Dang T; Liu GL; Li Y; Sun X; Zhou Z
Cell Death Dis; 2019 Jul; 10(8):550. PubMed ID: 31320608
[TBL] [Abstract][Full Text] [Related]
4. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
5. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Cai J; Su L; Luo W
Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
[TBL] [Abstract][Full Text] [Related]
6. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
7. MiR-140 leads to MRE11 downregulation and ameliorates oxaliplatin treatment and therapy response in colorectal cancer patients.
Horak J; Dolnikova A; Cumaogullari O; Cumova A; Navvabi N; Vodickova L; Levy M; Schneiderova M; Liska V; Andera L; Vodicka P; Opattova A
Front Oncol; 2022; 12():959407. PubMed ID: 36324569
[TBL] [Abstract][Full Text] [Related]
8. Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancer.
Zhang B; Chan SH; Liu XQ; Shi YY; Dong ZX; Shao XR; Zheng LY; Mai ZY; Fang TL; Deng LZ; Zhou DS; Chen SN; Li M; Zhang XD
J Cell Mol Med; 2021 Sep; 25(18):8836-8849. PubMed ID: 34378321
[TBL] [Abstract][Full Text] [Related]
9. The MMS22L-TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress.
Piwko W; Mlejnkova LJ; Mutreja K; Ranjha L; Stafa D; Smirnov A; Brodersen MM; Zellweger R; Sturzenegger A; Janscak P; Lopes M; Peter M; Cejka P
EMBO J; 2016 Dec; 35(23):2584-2601. PubMed ID: 27797818
[TBL] [Abstract][Full Text] [Related]
10. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
[TBL] [Abstract][Full Text] [Related]
11. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
[TBL] [Abstract][Full Text] [Related]
12. Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis.
Li Z; Bu D; Wang X; Zhu L; Lei D; Tang F; Sun X; Chen C; Ji X; Bai S
Onco Targets Ther; 2023; 16():703-721. PubMed ID: 37667747
[TBL] [Abstract][Full Text] [Related]
13. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b.
Wang W; Wang M; Xu J; Long F; Zhan X
Cancer Cell Int; 2020; 20():339. PubMed ID: 32760217
[TBL] [Abstract][Full Text] [Related]
15. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
16. Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells.
Cherradi S; Garambois V; Marines J; Andrade AF; Fauvre A; Morand O; Fargal M; Mancouri F; Ayrolles-Torro A; Vezzo-Vié N; Jarlier M; Loussaint G; Huvelle S; Joubert N; Mazard T; Gongora C; Pourquier P; Boissière-Michot F; Rio MD
Cell Biosci; 2023 Apr; 13(1):72. PubMed ID: 37041570
[TBL] [Abstract][Full Text] [Related]
17. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
18. The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.
Wang H; Wang X; Zhang H; Deng T; Liu R; Liu Y; Li H; Bai M; Ning T; Wang J; Ge S; Ba Y
Oncogene; 2021 Jul; 40(28):4695-4708. PubMed ID: 34140641
[TBL] [Abstract][Full Text] [Related]
19. FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.
Tong J; Shen Y; Chen X; Wang R; Hu Y; Zhang X; Zhang Z; Han L
Oncol Rep; 2019 Oct; 42(4):1404-1412. PubMed ID: 31524278
[TBL] [Abstract][Full Text] [Related]
20. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3β signaling.
Zhou Y; Yang L; Xiong L; Wang K; Hou X; Li Q; Kong F; Liu X; He J
J Cancer; 2021; 12(12):3741-3753. PubMed ID: 33995648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
